Original scientific paper

Topotecan in the treatment of recurrent ovarian cancer

Višnja Matković ; Gynecolgic Cancer Center, University Hospital Zagreb, Zagreb, Croatia
Ante Ćorušić ; Gynecolgic Cancer Center, University Hospital Zagreb, Zagreb, Croatia

Abstract

Topotecan is an efficacious agent in the treatment of ovarian cancer recurrence after the failure of primary chemotherapy with platinum and its derivatives.
Twenty-five patients with recurrent ovarian cancer were treated with topotecan at the Department of Gynecologic Oncology, Clinic for Gynecology and obstetrics, Clinical Hospital Zagreb in the period from January 2004 – January 2005.
All patients were primarily operated and assessed as stage III or IV of ovarian cancer, and therefore received chemotherapy with platinum (in combination with paclitaxel or cyclophosphamide). After their first recurrence in a less than a 6-month interval, topotecan was administered.
A complete clinical response was achieved in 2 patients (8%), a partial response in 15 patients (60%), progression in 8 patients (32%). All patients receiving topotecan were without early reactions (GI- nausea, vomiting), and experienced only mild late reactions (moderate myelosupression). Eight, 9, 6 and 2 patients received 6, 4, 2 and 1 treatment cycles, respectively.
Based upon the low number of patients included in the study, we may say that topotecan is well tolerated, without significant early and late side-effects and with satisfying treatment response in patients with recurrent ovarian cancer, who are resistant to chemotherapy with platinum.

Keywords

ovarian cancer; recurrence; topotecan

Hrčak ID:

281538

URI

https://hrcak.srce.hr/281538

Publication date:

30.11.2005.

Article data in other languages: croatian

Visits: 565 *